Glycosylation of PCSK9 Impairs its Interaction with LDLR But Assures its Stability

被引:0
|
作者
Pacheco-Velazquez, Silvia C.
Hay, Joshua
Rosario, Sara
Mueller, Paul A.
Pamir, Nathalie
机构
关键词
PCSK9; LDL;
D O I
10.1161/atvb.43.suppl_1.114
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A114
引用
收藏
页数:2
相关论文
共 50 条
  • [31] Sex difference in circulating PCSK9 and its clinical implications
    Jia, Fang
    Fei, Si-Fan
    Tong, De-Bing
    Xue, Cong
    Li, Jian-Jun
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [32] PAQR3 modulates blood cholesterol level by facilitating interaction between LDLR and PCSK9
    Huang, Meiqin
    Zhao, Zilong
    Cao, Qianqian
    You, Xue
    Wei, Siying
    Zhao, Jingyu
    Bai, Meijuan
    Chen, Yan
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2019, 94 : 88 - 95
  • [33] Disrupting the PCSK9/LDLR protein-protein interaction by an imidazole-based minimalist peptidomimetic
    Stucchi, Mattia
    Grazioso, Giovanni
    Lammi, Carmen
    Manara, Silvia
    Zanoni, Chiara
    Arnoldi, Anna
    Lesma, Giordano
    Silvani, Alessandra
    ORGANIC & BIOMOLECULAR CHEMISTRY, 2016, 14 (41) : 9736 - 9740
  • [34] 20(S)-Protopanaxadiol decreases atherosclerosis in ApoE KO mice by increasing the levels of LDLR and inhibiting its binding with PCSK9
    Huang, Ye-Wei
    Zhang, Meng
    Wang, Li-Tian
    Nie, Yan
    Yang, Jin-Bo
    Meng, Wen-Luer
    Wang, Xuan-jun
    Sheng, Jun
    FOOD & FUNCTION, 2022, 13 (13) : 7020 - 7028
  • [35] Variation at the PCSK9 and LDLR locus, LDL levels, and heart disease in PROSPER
    Polisecki, Eliana
    Muallem, Hind
    Maeda, Nolbuyo
    Trompet, Stella
    Julkema, Wouter
    McMahon, Alex
    Robetson, Michele
    Ford, Ian
    Blauw, Gerard
    Murphy, Michael
    Shepherd, James
    Schaefer, Ernst
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2007, 27 (06) : E116 - E116
  • [36] Euphornin L promotes lipid clearance by dual regulation of LDLR and PCSK9
    Li, Huihui
    Li, Jun
    Zhang, Xianjing
    Li, Jiaomeng
    Xi, Cong
    Wang, Wenqiong
    Lu, Youli
    Xuan, Lijiang
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2021, 22 (06)
  • [37] PCSK9 analysis in familial hypercholesterolaemia patients negative for LDLR and APOB mutations
    George, P. M.
    Homer, V. M.
    Laurie, A. D.
    Hurndell, N.
    Scott, R. S.
    ATHEROSCLEROSIS SUPPLEMENTS, 2006, 7 (03) : 135 - 135
  • [38] LDLR ACTIVITY AND SUBCELLULAR DISTRIBUTION IS SENSITIVE TO ESTROGEN IN MICE LACKING PCSK9
    Roubtsova, Anna
    Koschinsky, Marlys L.
    Seidah, Nabil G.
    Prat, Annik
    ATHEROSCLEROSIS SUPPLEMENTS, 2018, 32 : 61 - 61
  • [39] A review of PCSK9 inhibition and its effects beyond LDL receptors
    Dixon, Dave L.
    Trankle, Cory
    Buckley, Leo
    Parod, Eric
    Carbone, Salvatore
    Van Tassell, Benjamin W.
    Abbate, Antonio
    JOURNAL OF CLINICAL LIPIDOLOGY, 2016, 10 (05) : 1073 - 1080
  • [40] The LDLR, APOB, and PCSK9 Variants of Index Patients with Familial Hypercholesterolemia in Russia
    Meshkov, Alexey
    Ershova, Alexandra
    Kiseleva, Anna
    Zotova, Evgenia
    Sotnikova, Evgeniia
    Petukhova, Anna
    Zharikova, Anastasia
    Malyshev, Pavel
    Rozhkova, Tatyana
    Blokhina, Anastasia
    Limonova, Alena
    Ramensky, Vasily
    Divashuk, Mikhail
    Khasanova, Zukhra
    Bukaeva, Anna
    Kurilova, Olga
    Skirko, Olga
    Pokrovskaya, Maria
    Mikova, Valeriya
    Snigir, Ekaterina
    Akinshina, Alexsandra
    Mitrofanov, Sergey
    Kashtanova, Daria
    Makarov, Valentin
    Kukharchuk, Valeriy
    Boytsov, Sergey
    Yudin, Sergey
    Drapkina, Oxana
    GENES, 2021, 12 (01) : 1 - 17